Delsym XR Shortage: What Providers and Prescribers Need to Know in 2026

Every fall and winter, primary care providers, urgent care clinicians, and pharmacists field a familiar question from patients: "I can't find Delsym anywhere — what do I do?" While Delsym XR is an OTC medication and not a prescription-required product, clinicians play an important role in guiding patients toward equivalent alternatives and addressing the clinical nuances of cough management when preferred products are unavailable.

This guide is written for clinicians and pharmacists who need a clear, current overview of Delsym XR availability in 2026 and practical recommendations for patient management.

Current Availability Status (2026)

As of 2026, dextromethorphan polistirex extended-release suspension (Delsym XR) is not listed in the FDA's drug shortage database. OTC cough and cold products are not subject to the same FDA shortage reporting requirements as prescription drugs, meaning localized stockouts go untracked at the federal level.

Clinically relevant availability disruption occurs predictably during respiratory illness season (October through March), particularly during high-acuity flu years or multi-virus surges. Availability normalizes in late spring and through summer.

Clinical Pharmacology Reminder: Why Polistirex Matters

Delsym XR uses dextromethorphan polistirex, an ion-exchange resin complex that creates a controlled-release matrix. Unlike dextromethorphan hydrobromide (HBr) products — which have a half-life leading to 4 to 8 hours of action — the polistirex formulation provides antitussive coverage for up to 12 hours per dose.

Dextromethorphan acts centrally on the medullary cough center as an NMDA receptor antagonist and sigma-1 receptor agonist, raising the cough threshold without inhibiting mucociliary clearance. It is comparable to codeine as an antitussive but lacks analgesic, sedative, or respiratory depressant effects at therapeutic doses. It is not an opioid and is not DEA-scheduled.

Key Clinical Considerations When Recommending Alternatives

When guiding patients who cannot find Delsym XR, consider these clinical factors:

• Cough type: Dextromethorphan is indicated for dry, nonproductive cough. For productive coughs with significant sputum, guaifenesin (Mucinex) or mucolytics are more appropriate. Cough suppressants in productive cough can impair mucus clearance.
• MAOI interaction: All dextromethorphan products are absolutely contraindicated within 14 days of MAOI therapy due to risk of serotonin syndrome, hypertensive crisis, and death. This applies equally to all alternatives containing DXM.
• SSRI/SNRI patients: DXM inhibits serotonin reuptake, creating a moderate drug interaction risk with SSRIs and SNRIs. At standard OTC dosing, serotonin syndrome is rare but not impossible. Counsel patients to use the lowest effective dose for the shortest duration necessary.
• CYP2D6 poor metabolizers: Approximately 8–10% of the population are CYP2D6 poor metabolizers, resulting in higher plasma DXM concentrations at standard doses. Advise these patients to use the lowest effective dose.
• Pediatric patients: Delsym XR (dextromethorphan polistirex ER suspension) is approved for children ages 4 and older. DXM is not recommended for children under 4. For children, cough in acute respiratory illness often does not require pharmacologic suppression unless significantly disruptive.

Equivalent OTC Alternatives to Recommend

When Delsym XR is unavailable, the following alternatives are clinically equivalent or acceptable substitutes:

• Robitussin 12 Hour Cough Relief: Dextromethorphan polistirex 30 mg/5 mL ER suspension — therapeutically identical to Delsym XR.
• Generic DXM polistirex ER: Identical pharmacokinetics; available under store brands at CVS, Walgreens, Walmart, Target, Amazon.
• Dextromethorphan HBr IR (immediate-release): Same mechanism; requires dosing every 6–8 hours. Acceptable when the patient doesn't require extended-release coverage. Max 120 mg/day.

Prescription Alternatives When OTC Is Insufficient

For patients whose cough is not adequately controlled by OTC dextromethorphan:

• Benzonatate (Tessalon Perles) 100–200 mg TID: A non-narcotic antitussive that anesthetizes stretch receptors in lung parenchyma and pleura. No CYP2D6 interaction. Must be swallowed whole — capsule rupture can cause laryngospasm, cardiovascular collapse, or death.
• Codeine (Schedule V) cough formulations: Reserved for severe, refractory cough. Carries sedation, respiratory depression, constipation, and abuse potential. CYP2D6 polymorphism significantly affects metabolism.

How to Help Patients Find Delsym XR or Equivalents

Directing patients to medfinder can reduce the burden on your practice of fielding pharmacy-availability calls. medfinder is a paid service that calls pharmacies near a patient's location to check current stock and texts the patient the results. This works for prescription and OTC medications alike.

Summary for Clinical Practice

Delsym XR is not in an official FDA shortage in 2026 but is subject to seasonal localized stockouts. For most patients with dry, nonproductive cough, any dextromethorphan polistirex ER suspension is a direct equivalent. For patients on MAOIs, DXM is contraindicated — benzonatate is a safe alternative. For patients on SSRIs/SNRIs, counsel on serotonin syndrome risk and advise standard OTC dosing. When OTC options fail, benzonatate 100–200 mg TID is the preferred prescription alternative.

See also: How to help your patients find Delsym XR in stock.